Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Annals of the Rheumatic Diseases

Volumn 76, Issue 2, 2017, Pages 355-363

  Yoo, Dae Hyun ^a   Prodanovic, Nenad ^b   Jaworski, Janusz ^c   Miranda, Pedro ^d   Ramiterre, Edgar ^e   Lanzon, Allan ^f   Baranauskaite, Asta ^g   Wiland, Piotr ^h   Abud Mendoza, Carlos ⁱ   Oparanov, Boycho ^j   Smiyan, Svitlana ^k   Kim, Houng ^l   Lee, Sang Joon ^l   Kim, Suyeon ^l   Park, Won ^m  

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^b Clinical Center Banja Luka   (United Kingdom)

^c Reumatika Centrum Reumatologi   (Poland)

^d UNIVERSITY OF CHILE   (Chile)

^e Department of Surgery   (Philippines)

^f Mary Mediatrix Medical Center   (Philippines)

^g LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^h WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁱ UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^j MILITARY MEDICAL ACADEMY   (Bulgaria)

^k I HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^l Celltrion Inc   (South Korea)

^m Inha University   (South Korea)

more..

Author keywords

Anti TNF; DMARDs (biologic); Rheumatoid Arthritis; Treatment

Indexed keywords

INFLIXIMAB; INFLIXIMAB DYYB; METHOTREXATE; ANTIBODY; ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT; CT-P13; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BURSITIS; COHORT ANALYSIS; CONTROLLED STUDY; CONTUSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HERPES VIRUS INFECTION; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LATENT TUBERCULOSIS; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; UTERUS BLEEDING; VAGINITIS; ADOLESCENT; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLIXIMAB; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84966417145     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208786     Document Type: Article

References (46)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Kuek A, Hazleman BL, Ostör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60.
3. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 2013;12:835-8.
4. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005;65:661-94.
5. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206.
6. Fischer MA, Polinski JM, Servi AD, et al. Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs. Arthritis Rheum 2008;59:1611-17.
7. Pease C, Pope JE, Truong D, et al. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 2011;41:81-9.
8. Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009;68:1666-72.
9. Desai RJ, Rao JK, Hansen RA, et al. Predictors of treatment initiation with tumor necrosis factor-alpha inhibitors in patients with rheumatoid arthritis. J Manag Care Pharm 2014;20:1110-20.
10. World Health Organization, Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed 4 Apr 2016).
11. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicine Products (CHMP/437/04 Rev 1).
12. October 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf (accessed 4 Apr 2016).
13. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. April 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf (accessed 4 Apr 2016).
14. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-83.
15. Generics and Biosimilars Initiative. Biosimilars approved in Europe. 2016. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe (accessed 4 Apr 2016).
16. Horl WH, Locatelli F, Haag-Weber M, et al. Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10-12 g/dl. Clin Nephrol 2012;78:24-32.
17. Krivoshiev S, Todorov VV, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008;24:1407-15.
18. Krivoshiev S, Wizemann V, Czekalski S, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010;27:105-17.
19. Davis-Ajami ML, Wu J, Downton K, et al. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics 2014;8:155-67.
20. Haag-Weber M, Eckardt KU, Horl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-alpha (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77:8-17.
21. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 2012;7(Suppl 1):S29-34.
22. del Giglio A, Eniu A, Ganea-Motan D, et al. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332.
23. Engert A, Griskevicius L, Zyuzgin Y, et al. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374-9.
24. Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Technol 2011;5:741-54.
25. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab). 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002576/WC500151486.pdf (accessed 4 Apr 2016).
26. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima®. mAbs 2014;6:1163-77.
27. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
28. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82.
29. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
30. Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther 2016;18:25.
31. Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014;15 (Suppl 1):S5-11.
32. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
33. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
34. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
35. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
36. Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8.
37. Park W, Woo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346-54.
38. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
39. Plasencia C, Pascual-Salcedo D, Nuño L, et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955-60.
40. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
41. Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009;72:380-90.
42. Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 2008;24:625-37.
43. Wiȩcek A, Ahmed I, Scigalla P, et al. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther 2010;27:941-52.
44. Lubenau H, Bias P, Maly AK, et al. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial®. BioDrugs 2009;23:43-51.
45. Verpoort K, Möhler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 2012;4:289-93.
46. Flodmark CE, Lilja K, Woehling H, et al. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther 2013;3:35-43.